-
GH Research NASDAQ:GHRS GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
Location: 28 Baggot Street, Leinster, D02 NX43, Ireland | Website: www.ghres.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
281.3M
Cash
151.3M
Avg Qtr Burn
-9.489M
Short % of Float
22.98%
Insider Ownership
40.39%
Institutional Own.
58.95%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Bipolar depression, Postpartum depression | Phase 2a Data readout | |
GH002 (IV mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Update | |
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression | Phase 1 Initiation |